Pay in 4 interest-free payments of $7.39 Learn more
Ships within 48 hours · Estimated delivery Sep 28 - Oct 3
The study was industry-funded
Take our quick assessment to get started with a complimentary consultation
La Administracin de Alimentos y Medicamentos aprob el mircoles el medicamento para la diabetes Mounjaro del fabricante de medicamentos Eli Lilly como tratamiento para bajar de peso bajo el nombre de Zepbound para adultos obesos o con sobrepeso y con al menos una afeccin relacionada con el peso, como presin arterial alta, y los expertos dicen eventualmente podra convertirse en la droga ms vendida de todos los tiempos
CMS Issues Coverage Guidance on GLP-1 Anti-Obesity Drugs: Implications for Health Plans Posted on April 5, 2024 CMS Issued Coverage Guidance on GLP-1 Anti-Obesity Drugs Requiring Considerations for Health Plans GLP-1s (glucagon-like peptide 1 agonist) came up in the news again after the Centers for Medicare and Medicaid Services (CMS) issued coverage guidance on GLP-1 anti-obesity drugs with expanded indications on March 20, 2024.* Since the inception of Medicare Part D, drugs used for weight loss have been excluded from basic coverage
US$ 21.92
US$ 29.16
US$ 26.74
US$ 20.51
